This Lead and Inform Clinical Reference Group (CRG) covers Haematopoietic Stem Cell Transplantation (HSCT) services. Also known as Blood and Marrow Transplantation (BMT), the intervention is used to treat a wide spectrum of haematological and non-haematological disorders. The most common clinical indications for HSCT are leukaemias, lymphomas and myeloma.

Scope

This Clinical Reference Group (CRG) covers:

• Haematopoietic Stem Cell Transplantation (HSCT) services, also known as Blood and Marrow Transplantation (BMT).

Membership

• Dr Fiona Dignan, National Specialty Advisor (Chair)
• Dr Victoria Potter, Clinical Member
• Elizabeth Davies, Clinical Member
• Dr James Griffin, Clinical Member
• Dr Mary Slatter, Clinical Member
• Dr Adrian Bloor, Clinical Member
• Dr Deborah Richardson, Clinical Member
• Yasmin Sheikh, Affiliate Member (Anthony Nolan)
• Eduardo Olavarria, Affiliate Member (British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)
• Dr Giles Ratcliffe, Public Health Lead
• Anna Kafkalias, Lead Commissioner
• Sophie Mulligan, Patient & Public Voice
• George Norton, Patient & Public Voice
• Yasmin Sheikh, Affiliate Member – Anthony Nolan
• Jon Smythe, Affiliate Member – NHSBT
• Beki James, Affiliate Member – National paediatric British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)
• John Snowden, Affiliate Member – BSBMTCT (past president)
• Julia Lee, Affiliate Member – BSBMTCT

Products

A main part of the CRG’s work is the delivery of the ‘products of commissioning. These are the tools used by commissioners to contract services on an annual basis.

Service specifications

Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe both core and developmental service standards. Core standards are those that all funded providers should be able to demonstrate, with developmental standards being those which may require further changes in practice over time to provide excellence in the field.

The following service specifications fall within the scope of this CRG:

• Severe Combined Immunodeficiency and Related Disorders Service (children) – in partnership with the Women and Children’s NPOC
• Haematopoietic Stem Cell Transplantation (Adult)
• Haematopoietic Stem Cell Transplantation (Children)
• Paroxysmal Nocturnal Haemoglobinuria Service (Adults and Adolescents)

Policies

Commissioned

• Allogeneic haematopoietic Stem cell transplant for primary Iimmunodeficiencies (all ages)
• Defibrotide for severe veno-occlusive disease following stem cell transplant
• Haematopoietic stem cell transplantation (HSCT) (all ages)
• Haematopoietic stem cell transplantation (HSCT) – lymphoplasmacytic lymphoma
• Plerixafor for stem cell mobilisation in adults and children
• Second allogeneic haematopoietic stem cell transplant for relapsed disease
• Sorafenib maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT)
• Treatments for graft versus host disease (GvHD) following haematopoietic stem cell transplantation
• Use of therapeutic immunoglobulin in England

Get involved

If you are interested in the work of the BMT CRG or its NPoC, you can register as a stakeholder.

For details on our latest consultations please visit the NHS England consultation hub.

Get in contact

For any questions or queries relating to the work of the BMT CRG or its NPOC, please contact: england.npoc-bloodandinfection@nhs.net